Cargando…

Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Hemophilia A in India

PURPOSE: Hemophilia A is an X-linked congenital disorder, characterized by factor VIII (FVIII) deficiency. Globally, India has the highest population of patients with hemophilia, and there is a clear unmet need for appropriate and effective treatment for this patient population. This multicenter, op...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choraria, Nirmalkumar, Rangarajan, Savita, John, M. Joseph, Apte, Shashikant, Gupta, Pritam, Pai, Seema, Chand, Rohit, Parvatini, Shyam, Ramakanth, G. S. H., Rupon, Jeremy, Chhabra, Amit, Muley, Hitesh Bhaskarrao, Simoneau, Damien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer India 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9702934/ https://www.ncbi.nlm.nih.gov/pubmed/36467512 http://dx.doi.org/10.1007/s12288-022-01587-1

Ejemplares similares

Nonacog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Moderately Severe or Severe Hemophilia B in India
por: Choraria, Nirmalkumar, et al.
Publicado: (2022)

Assessment of Relative Bioavailability of Moroctocog Alfa and Moroctocog Alfa (AF‐CC) in Subjects With Severe Hemophilia A
por: Korth‐Bradley, Joan, et al.
Publicado: (2018)

Safety and Efficacy of Moroctocog Alfa (AF-CC) in Chinese Patients with Hemophilia A: Results of Two Open-Label Studies
por: Yang, Renchi, et al.
Publicado: (2020)

RNAi for the Treatment of People with Hemophilia: Current Evidence and Patient Selection
por: Boyce, Sara, et al.
Publicado: (2023)

Turoctocog alfa is safe for the treatment of Indian patients with hemophilia A: Guardian 10 trial results
por: John, M. Joseph, et al.
Publicado: (2020)

Profile of efraloctocog alfa and its potential in the treatment of hemophilia A
por: George, Lindsey A, et al.
Publicado: (2015)

The Effect of Fluctuating Temperature on the Stability of Turoctocog Alfa for Hemophilia A
por: Napolitano, Mariasanta, et al.
Publicado: (2019)

Damoctocog Alfa Pegol for Hemophilia A Prophylaxis: An Italian Multicenter Survey
por: Zanon, Ezio
Publicado: (2023)

Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia A
por: Vashi, Parth, et al.
Publicado: (2021)

Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa
por: Lissitchkov, Toshko, et al.
Publicado: (2023)

Turoctocog alfa: an evidence-based review of its potential in the treatment of hemophilia A
por: Takedani, Hideyuki, et al.
Publicado: (2015)

Efficacy, Safety, and Pharmacokinetics of Beroctocog Alfa in Patients Previously Treated for Hemophilia A
por: Hyun, Shin Young, et al.
Publicado: (2015)

Surgery and Prophylaxis with Susoctocog-Alfa in Acquired Hemophilia: Case Series and Literature Review
por: Sella, Carola, et al.
Publicado: (2023)

Apixaban and eftrenonacog alfa treatment in a patient with moderate hemophilia B and cardiovascular disease
por: Santoro, Rita C., et al.
Publicado: (2021)

Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study
por: Lissitchkov, Toshko, et al.
Publicado: (2022)

Neurosurgery in a patient with severe hemophilia B: an experience using eftrenonacog alfa as perioperative management
por: Benitez Hidalgo, Olga, et al.
Publicado: (2022)

Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate(®)) in hemophilia A
por: Chowdary, Pratima, et al.
Publicado: (2016)

Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis
por: Mancuso, Maria Elisa, et al.
Publicado: (2021)

The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A
por: Male, Christoph, et al.
Publicado: (2022)

Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B Patients
por: Faraj, Alan, et al.
Publicado: (2023)

Adenovirus‐associated antibodies in UK cohort of hemophilia patients: A seroprevalence study of the presence of adenovirus‐associated virus vector–serotypes AAV5 and AAV8 neutralizing activity and antibodies in patients with hemophilia A
por: Stanford, Sophia, et al.
Publicado: (2019)

Seroprevalence to adeno‐associated virus type 6 in people with hemophilia B from a UK adult cohort
por: Boyce, Sara, et al.
Publicado: (2022)

Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study
por: Patel, Nayana Hitesh, et al.
Publicado: (2023)

Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa
por: Lentz, S R, et al.
Publicado: (2014)

Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP)
por: Klamroth, Robert, et al.
Publicado: (2021)

Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety
por: Mahlangu, Johnny, et al.
Publicado: (2021)

Medial Sural Artery Perforator Flap for Head and Neck Reconstruction
por: Agrawal, Gunjan, et al.
Publicado: (2018)

ALFA
por: Hiller, Karlheinz
Publicado: (2012)

Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program
por: Lissitchkov, Toshko, et al.
Publicado: (2019)

Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1)
por: Klamroth, Robert, et al.
Publicado: (2019)

External qualification of the Web‐Accessible Population Pharmacokinetic Service–Hemophilia (WAPPS‐Hemo) models for octocog alfa using real patient data
por: Chelle, Pierre, et al.
Publicado: (2021)

Efficacy of Platelet-Rich Plasma and Concentrated Growth Factor in Treating Androgenetic Alopecia - A Retrospective Study
por: Steward, Enosh Nirmalkumar, et al.
Publicado: (2020)

AFS Monitoring: The CERN AFS Console
por: Wiebalck, Arne
Publicado: (2008)

Efficacy of Nuwiq(®) (Simoctocog Alfa) in Patients with Hemophilia A Who Changed and Adhered to a Pharmacokinetic-Guided Prophylaxis Regimen in the NuPreviq Study
por: Pasi, K John
Publicado: (2021)

Recombinant follitropin alfa/lutropin alfa in fertility treatment
por: Gibreel, Ahmed, et al.
Publicado: (2010)

Venous Thrombosis in Acquired Hemophilia: The Complex Management of Competing Pathologies
por: Chhabra, Manu, et al.
Publicado: (2019)

Complete chloroplast genomes of the Chlamydomonas reinhardtii nonphotosynthetic mutants CC-1375, CC-373, CC-4199, CC-2359 and CC-1051
por: DeShaw, Alexandra E., et al.
Publicado: (2017)

Mug{AF}amar{AF}at Farn{AF}ats{AF}i == Farnatchi au bal masqué == Farnatchi at the masked ball /
por: Fayard, Roland
Publicado: (1997)

First open-label, single-arm, prospective study of real-world use of FIX replacement therapy in a predominantly pediatric hemophilia B population in China
por: Yang, Renchi, et al.
Publicado: (2021)

Efanesoctocog alfa elicits functional clot formation that is indistinguishable to that of recombinant factor VIII
por: Demers, Melanie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4v71aa0qe9flchi2eu6b81j59d